Home › Diffuse Large B-Cell Lymphoma › Oregon › Portland
Diffuse Large B-Cell Lymphoma clinical trials in Portland, OR
15 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in and around Portland (within about 30 miles). Open a study to see who can join and how to contact the study team.
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
RecruitingPhase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
RecruitingPhase 2
- Providence Portland Medical Center ( Site 0120), Portland
- Providence Oncology and Hematology Clinic Westside ( Site 0179), Portland
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RecruitingPhase 3
- Kaiser Permanente Interstate Medical Office - Central ( Site 0181), Portland
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
RecruitingObservational study
- OHSU Knight Cancer Institute, Portland
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RecruitingPhase 1
- Oregon Health & Science University (OHSU), Portland
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RecruitingPhase 1/2
- Oregon Health and Science University ( Site 1004), Portland
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
RecruitingPhase 2
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RecruitingPhase 2
- Oregon Health and Science University, Portland
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RecruitingPhase 1/2
- Oregon Health & Science University, Portland
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
RecruitingObservational study
- Oregon Health and Science University Knight Cancer Institute, Portland
DALY II USA/ MB-CART2019.1 for DLBCL
RecruitingPhase 2
- Oregon Health and Science University Knight Cancer Institute, Portland
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
RecruitingPhase 1/2
- OHSU Knight Cancer Institute, Portland
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
RecruitingPhase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
- and 1 more
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
RecruitingPhase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12 mi away
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
RecruitingPhase 1
- Oregon Health & Science University, Portland
Diffuse Large B-Cell Lymphoma trials in other cities
- New York City, NY21 studies
- Baldwin Park, CA19 studies
- Chicago, IL18 studies
- Houston, TX17 studies
- Los Angeles, CA17 studies
- Milwaukee, WI16 studies
- Boston, MA16 studies
- Philadelphia, PA15 studies
- Durham, NC14 studies
- Nashville, TN14 studies
- Dallas, TX13 studies
- Seattle, WA12 studies
Other studies in Portland
- Non-Small Cell Lung Cancer45 studies
- Cancer (all types)36 studies
- Prostate Cancer33 studies
- Breast Cancer32 studies
- Metastatic Cancer30 studies
- Colorectal Cancer28 studies
- Lung Cancer26 studies
- Ovarian Cancer26 studies
- Acute Myeloid Leukemia25 studies
- Endometrial Cancer24 studies
- Pancreatic Cancer19 studies
- Head and Neck Squamous Cell Carcinoma18 studies
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.